Published in Blood Weekly, March 30th, 2000
ReFacto was developed by the Genetics Institute of Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products. ReFacto Antihemophilic Factor (Recombinant) is the first recombinant factor VIII product formulated without human serum albumin to be approved by the FDA. ReFacto is indicated for the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.